New DNA scanner could spot hidden cancer clues

NCT ID NCT05714592

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new technique called optical genome mapping (OGM) to find genetic changes in blood cancers like polycythemia vera, essential thrombocythemia, and myelofibrosis. Researchers will compare OGM with standard genetic tests in 300 patients who need a bone marrow exam. The goal is to see if OGM can detect more or different genetic abnormalities, which could improve how these diseases are diagnosed and managed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a more sensitive and comprehensive genetic test for these blood cancers, improving diagnosis and risk assessment.
What could go wrong: This is an early-stage observational study comparing a new technique to standard methods. It may not show clear advantages, and the new method might not be adopted in routine practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLONALITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera essential thrombocythemia Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLONALITY CYTOGENETICS MYELOPROLIFERATIVE NEOPLASM OPTICAL GENOME MAPPING PROGNOSTIC STRATIFICATION

Contacts and locations

Locations

Centre Hospitalier Universitaire d'Amiens
RECRUITING

Amiens, Picardie, 80000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.